ADAG logo

Adagene Inc.

ADAG
Healthcare|Biotechnology|CN
$2.00
-0.02 (-0.99%)
Tangible Book / Share
$2.34
Cash / Share
$2.82
Next Earnings Report
Mar 31, 2027
EPS est. -$0.21
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Apr 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (5)

Dec 2026
Est. completion
P1P2Advanced Solid Tumor
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
NCT05491083n=51
Jun 2027
Est. completion
P1P2Advanced/Metastatic Solid Tumors
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT05405595n=186
Jul 2027
Est. completion
P1P2Advanced Liver Cancers
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
NCT04524871n=518
Dec 2027
Est. completion
P1P2HER2-negative Breast Cancer
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
NCT05275777n=66
Dec 2027
Est. completion
P2Locally Advanced Colorectal Cancer
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
NCT06846268n=20

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2025
P1
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
NCT05614258

Recent Press Releases

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Oct 28, 2026 · GlobeNewsWire
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Oct 27, 2026 · GlobeNewsWire
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
Oct 14, 2026 · GlobeNewsWire
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Sep 22, 2026 · GlobeNewsWire
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Sep 10, 2026 · GlobeNewsWire
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Sep 9, 2026 · GlobeNewsWire
Adagene to Participate in Three Upcoming Investor Conferences
Aug 20, 2026 · GlobeNewsWire
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Aug 12, 2026 · GlobeNewsWire

SEC Filings (46)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 25, 20266-KForeign issuer reportDocumentIndex
Sep 22, 20266-KForeign issuer reportDocumentIndex
Sep 10, 20266-KForeign issuer reportDocumentIndex
Sep 9, 20266-KForeign issuer reportDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 20266-KForeign issuer reportDocumentIndex
Jul 6, 20266-KForeign issuer reportDocumentIndex
Jun 8, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 17, 20266-KForeign issuer reportDocumentIndex
Apr 2, 2026424B5Offering prospectusDocumentIndex
Apr 2, 20266-KForeign issuer reportDocumentIndex
Apr 2, 2026424B5Offering prospectusDocumentIndex
Apr 2, 20266-KForeign issuer reportDocumentIndex
Apr 1, 20266-KForeign issuer reportDocumentIndex
Apr 1, 202620-FAnnual report (foreign)DocumentIndex
Mar 18, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 29, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 23, 20266-KForeign issuer reportDocumentIndex
Jan 9, 2026EFFECTDocumentIndex
Jan 9, 2026424B3Offering prospectusDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 13, 20256-KForeign issuer reportDocumentIndex
Oct 31, 2025F-3Shelf registrationDocumentIndex
Aug 12, 20256-KForeign issuer reportDocumentIndex
Jul 15, 20256-KForeign issuer reportDocumentIndex
Jul 2, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 1, 20256-KForeign issuer reportDocumentIndex
May 30, 2025EFFECTDocumentIndex
May 30, 2025424B5Offering prospectusDocumentIndex
May 23, 2025F-3/AShelf registrationDocumentIndex
May 22, 20256-KForeign issuer reportDocumentIndex
May 15, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 9, 2025F-3Shelf registrationDocumentIndex
Mar 24, 202520-FAnnual report (foreign)DocumentIndex
Mar 24, 20256-KForeign issuer reportDocumentIndex